ST6GALNAC4
Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-sialyltransferase
Also known as: SIA7D_HUMAN, SIAT3C, SIAT7D, ST6GALNACIV
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H4F1
- Gene
- ST6GALNAC4
- Ensembl
- ENSG00000136840
- Chromosome
- 9
- Canonical length
- 302 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Golgi apparatus
OverviewNCBI Gene
The protein encoded by this gene is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates. The encoded protein prefers glycoproteins rather than glycolipids as substrates and shows restricted substrate specificity, utilizing only the trisaccharide sequence Neu5Ac-alpha-2,3-Gal-beta-1,3-GalNAc. In addition, it is involved in the synthesis of ganglioside GD1A from GM1B. The encoded protein is normally found in the Golgi apparatus but can be proteolytically processed to a soluble form. This protein is a member of glycosyltransferase family 29. Transcript variants encoding different isoforms have been found for this gene. Readthrough transcripts exist for this gene and the downstream ST6GALNAC6 gene. [provided by RefSeq, Jan 2022]
Canonical amino-acid sequenceUniProt
302 residues, UniProt reviewed canonical sequence.
>Q9H4F1|ST6GALNAC4
1 MKAPGRLVLI ILCSVVFSAV YILLCCWAGL PLCLATCLDH HFPTGSRPTV PGPLHFSGYS
61 SVPDGKPLVR EPCRSCAVVS SSGQMLGSGL GAEIDSAECV FRMNQAPTVG FEADVGQRST
121 LRVVSHTSVP LLLRNYSHYF QKARDTLYMV WGQGRHMDRV LGGRTYRTLL QLTRMYPGLQ
181 VYTFTERMMA YCDQIFQDET GKNRRQSGSF LSTGWFTMIL ALELCEEIVV YGMVSDSYCR
241 EKSHPSVPYH YFEKGRLDEC QMYLAHEQAP RSAHRFITEK AVFSRWAKKR PIVFAHPSWR
301 TELocalizationUniProt · AlphaFold · HPA
Whether an antibody against ST6GALNAC4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 69 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 69 nTPM
- bone marrow: 38 nTPM
- spleen: 35 nTPM
- heart muscle: 32 nTPM
- lung: 26 nTPM
- blood vessel: 24 nTPM
Single-cell type
- pdcs: 99 nCPM
- plasma cells: 87 nCPM
- megakaryocytes: 74 nCPM
- alveolar cells type 2: 71 nCPM
- erythrocyte progenitors: 60 nCPM
- decidual stromal cells: 49 nCPM
Immune cell
- plasmacytoid DC: 234 nTPM
- memory B-cell: 25 nTPM
- NK-cell: 19 nTPM
- naive B-cell: 19 nTPM
- non-classical monocyte: 15 nTPM
- memory CD8 T-cell: 13 nTPM
Brain region
- choroid plexus: 20 nTPM
- cerebral cortex: 18 nTPM
- cerebellum: 18 nTPM
- hippocampal formation: 17 nTPM
- amygdala: 17 nTPM
- medulla oblongata: 16 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.39
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.76
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- ganglioside biosynthetic process
- glycolipid metabolic process
- oligosaccharide metabolic process
- protein O-linked glycosylation via N-acetyl-galactosamine
- viral protein processing
Molecular functions
- alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase activity
- alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide 6-alpha-sialyltransferase activity
- sialyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ST6GALNAC4 as an antibody target. Whether an autoantibody or antibody against ST6GALNAC4 could matter depends on whether native ST6GALNAC4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ST6GALNAC4 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ST6GALNAC4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...